(Q38007833)

26 August 2017

title

Therapies for allergic inflammation: refining strategies to induce tolerance (English)

1 reference

26 August 2017

0 references

1

Cezmi A Akdis

1 reference

26 August 2017

language of work or name

English

0 references

publication date

4 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

18

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

736-749

1 reference

TNFalpha blockade in human diseases: an overview of efficacy and safety

26 August 2017

cites work

1 reference

12 December 2020

Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects

1 reference

12 December 2020

Treatment of cat allergy with T-cell reactive peptides

1 reference

12 December 2020

Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy

1 reference

12 December 2020

Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells

1 reference

12 December 2020

Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities

1 reference

12 December 2020

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

1 reference

12 December 2020

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

1 reference

12 December 2020

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

1 reference

12 December 2020

Evidence that vitamin D(3) promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice

1 reference

12 December 2020

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

1 reference

12 December 2020

Asthma phenotypes: the evolution from clinical to molecular approaches

1 reference

12 December 2020

Vaccination with genetically engineered allergens prevents progression of allergic disease.

1 reference

12 December 2020

Immunomodulatory mast cells: negative, as well as positive, regulators of immunity

1 reference

12 December 2020

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

1 reference

12 December 2020

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

1 reference

12 December 2020

Multitargeted approach using antisense oligonucleotides for the treatment of asthma

1 reference

12 December 2020

Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells

1 reference

12 December 2020

Allergen-specific immunotherapy with recombinant grass pollen allergens

1 reference

12 December 2020

CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung

1 reference

12 December 2020

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

1 reference

12 December 2020

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies

1 reference

12 December 2020

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases.

1 reference

12 December 2020

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding

1 reference

12 December 2020

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

12 December 2020

Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

1 reference

12 December 2020

Bypassing IgE and targeting T cells for specific immunotherapy of allergy

1 reference

12 December 2020

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

12 December 2020

Evidence of a role of tumor necrosis factor alpha in refractory asthma

1 reference

12 December 2020

Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice.

1 reference

12 December 2020

Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression

1 reference

12 December 2020

Unmet needs in severe chronic upper airway disease (SCUAD).

1 reference

12 December 2020

A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation

1 reference

12 December 2020

Rituximab and omalizumab in severe, refractory insulin allergy.

1 reference

12 December 2020

Competence and competition: the challenge of becoming a long-lived plasma cell

1 reference

12 December 2020

Role of interleukin 10 in specific immunotherapy

1 reference

12 December 2020

Thymic stromal lymphopoietin interferes with airway tolerance by suppressing the generation of antigen-specific regulatory T cells

1 reference

12 December 2020

Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy

1 reference

12 December 2020

Anti-CD20 (rituximab) treatment improves atopic eczema

1 reference

12 December 2020

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

1 reference

12 December 2020

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

1 reference

12 December 2020

Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma

1 reference

12 December 2020

The development of allergic inflammation

1 reference

12 December 2020

Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab

1 reference

12 December 2020

What targeting eosinophils has taught us about their role in diseases

1 reference

12 December 2020

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

12 December 2020

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

1 reference

12 December 2020

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

1 reference

12 December 2020

Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes

1 reference

12 December 2020

The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge

1 reference

12 December 2020

Allergy and hypersensitivity: mechanisms of allergic disease

1 reference

12 December 2020

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

1 reference

12 December 2020

Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors

1 reference

12 December 2020

Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization *

1 reference

12 December 2020

Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

1 reference

12 December 2020

Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation

1 reference

12 December 2020

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model

1 reference

12 December 2020

Lebrikizumab treatment in adults with asthma

1 reference

12 December 2020

Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.

1 reference

12 December 2020

A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

1 reference

12 December 2020

IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets.

1 reference

12 December 2020

Tracking antigen-specific T-cells during clinical tolerance induction in humans

1 reference

12 December 2020

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

12 December 2020

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial

1 reference

12 December 2020

Asthma & COPD--IQPC's Second Conference

1 reference

12 December 2020

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

12 December 2020

Origins of CD4(+) effector and central memory T cells

1 reference

12 December 2020

A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells

1 reference

12 December 2020

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

1 reference

12 December 2020

A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.

1 reference

12 December 2020

Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis

1 reference

12 December 2020

Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells

1 reference

12 December 2020

In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure

1 reference

12 December 2020

Anti-CD20 (rituximab) treatment for atopic eczema

1 reference

12 December 2020

A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa

1 reference

12 December 2020

Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases.

1 reference

12 December 2020

An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation

1 reference

12 December 2020

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

12 December 2020

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

1 reference

12 December 2020

House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells

1 reference

12 December 2020

Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

1 reference

12 December 2020

Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease

1 reference

12 December 2020

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

1 reference

12 December 2020

Inhibitory effect of the new orally active CCR4 antagonist K327 on CCR4+CD4+ T cell migration into the lung of mice with ovalbumin-induced lung allergic inflammation

1 reference

12 December 2020

Churg-Strauss vasculitis in a patient treated with omalizumab

1 reference

12 December 2020

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

1 reference

12 December 2020

Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354).

1 reference

12 December 2020

Therapeutic manipulation of immune tolerance in allergic disease

1 reference

12 December 2020

Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

1 reference

12 December 2020

The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling

1 reference

12 December 2020

Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab.

1 reference

12 December 2020

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

12 December 2020

Association between CD4+CD25high T cells and atopy in children

1 reference

12 December 2020

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study

1 reference

12 December 2020

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

1 reference

12 December 2020

Immunomodulators for allergic respiratory disorders

1 reference

12 December 2020

Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma.

1 reference

12 December 2020

Dual nature of T cell-epithelium interaction in chronic rhinosinusitis.

1 reference

12 December 2020

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

1 reference

12 December 2020

Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway

1 reference

12 December 2020

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

1 reference

12 December 2020

Infliximab in the treatment of moderate to severe atopic dermatitis

1 reference

12 December 2020

Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis

1 reference

12 December 2020

A chimeric human-cat fusion protein blocks cat-induced allergy

1 reference

12 December 2020

CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2 granulomatous pathology caused by schistosome infection

1 reference

12 December 2020

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

1 reference

12 December 2020

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

12 December 2020

Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

1 reference

12 December 2020

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

12 December 2020

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.

1 reference

12 December 2020

Orchestrating the orchestrators: chemokines in control of T cell traffic

1 reference

12 December 2020

Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen bindin

1 reference

12 December 2020

Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy.

1 reference

12 December 2020

Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy

1 reference

12 December 2020

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

1 reference

12 December 2020

Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy.

1 reference

12 December 2020

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

1 reference

12 December 2020

Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells

1 reference

12 December 2020

CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction.

1 reference

12 December 2020

Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1

1 reference

12 December 2020

IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice

1 reference

12 December 2020

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

1 reference

12 December 2020

Diagnosis and management of drug hypersensitivity reactions

1 reference

12 December 2020

Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses

1 reference

12 December 2020

Allergens and their role in the allergic immune response

1 reference

12 December 2020

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

12 December 2020

Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance

1 reference

12 December 2020

Differentiation and functional analysis of human T(H)17 cells.

1 reference

12 December 2020

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

1 reference

12 December 2020

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

12 December 2020

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

1 reference

12 December 2020

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

1 reference

12 December 2020

An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions

1 reference

12 December 2020

Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes

1 reference

12 December 2020

Foxp3+ follicular regulatory T cells control the germinal center response.

1 reference

12 December 2020

TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis

1 reference

12 December 2020

Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial

1 reference

12 December 2020

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

1 reference

12 December 2020

Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy

1 reference

12 December 2020

Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial

1 reference

12 December 2020

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

1 reference

12 December 2020

Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro

1 reference

12 December 2020

Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa

1 reference

12 December 2020

Inhibition of complement activation by IgG4 antibodies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.2754

1 reference

26 August 2017

1 reference